Compare Amylx Pharmaceuticals Inc (AMLX) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Vipshop Holdings Ltd - ADR trades at $13.94 (market cap $6.69B). The key difference: Vipshop Holdings Ltd - ADR is far larger — about 3.4× Amylx Pharmaceuticals Inc's market cap, and Vipshop Holdings Ltd - ADR pays a 4.45% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | VIPS | |
|---|---|---|
Market Cap | $1.98B | $6.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $20.68 |
52-Week Low | $7.64 | $12.92 |
Enterprise Value | $1.70B | $3.29B |
Dividend Yield | — | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Vipshop Holdings (VIPS) trades at $13.94, up 0.65% with a bullish technical signal despite mixed earnings history. The stock shows attractive valuation metrics with P/E of 6.36 and P/S of 0.45, supported by solid profitability including 18.43% ROE. Recent Q1 2026 earnings matched expectations while the company pursues growth through outlet store strategies.
The outlook remains positive with analyst consensus favoring Buy ratings (53.57%) and improving cash flow trends. Key risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds, but strong fundamentals and institutional support suggest potential for upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
